Mitsubishi Tanabe picks up North American rights to Toray's nalfurafine
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharma (MTP) has acquired for undisclosed terms the development and commercialisation rights in North America to Toray's nalfurafine (TRK-820).